Equity Research
William Blair research analyst Tim Lugo was quoted in Barron’s on the topic of “genetic scissors” and the use of the new approach to pharmaceutical development being used by companies focused on gene therapy, including CRISPR.
“We believe Casgevy’s launch trajectory will follow a cadence similar to other cell therapies,” Lugo wrote in the note that was quoted in the publication.
Stay up-to-date with the latest William Blair news and insights
Jed Dorsheimer welcomes Doomberg for an in-depth discussion on the complexities of renewable energy integration and its impact on grid efficiency, exploring the challenges posed by the variability of renewables, the resurgence of nuclear power, and the critical role of natural gas in bridging the energy transition.
William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, is thrilled to announce its performance in the annual Coalition Greenwich Voice of the Client – 2024 North American Equity Investors Study.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
